Literature DB >> 31513851

Optical coherence tomography diagnostic signs in posterior uveitis.

Francesco Pichi1, Alessandro Invernizzi2, William R Tucker3, Marion R Munk4.   

Abstract

A diagnostic sign refers to a quantifiable biological parameter that is measured and evaluated as an indicator of normal biological, pathogenic, or pharmacologic responses to a therapeutic intervention. When used in translational research discussions, the term itself often alludes to a sign used to accelerate or aid in diagnosis or monitoring and provide insight into "personalized" medicine. Many new diagnostic signs are being developed that involve imaging technology. Optical coherence tomography is an imaging technique that provides in vivo quasi-histological images of the ocular tissues and as such it's able to capture the structural and functional modifications that accompany inflammation and infection of the posterior part of the eye. From the hyperreflective inflammatory cells and deposits in the vitreous and on the hyaloid, to the swollen photoreceptors bodies in multiple evanescent white dots syndrome, and from optical differences in the subretinal fluid compartments in Vogt-Koyanagi-Harada disease to the hyporeflective granulomas in the choroid, these tomographical signs can be validated to reach the status of biomarkers. Such non-invasive imaging diagnostic signs of inflammation can be very useful to clinicians seeking to make a diagnosis and can represent a dataset for machine learning to offer a more empirical approach to the detection of posterior uveitis.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Diagnostic signs; Infectious uveitis; Optical coherence tomography; Posterior uveitis

Mesh:

Year:  2019        PMID: 31513851     DOI: 10.1016/j.preteyeres.2019.100797

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  7 in total

1.  Changes in choroidal imaging parameters following adalimumab therapy for refractory noninfectious uveitis.

Authors:  Ryuto Nishisho; Sentaro Kusuhara; Noriyuki Sotani; Kyong Woo Kim; Atsuko Katsuyama-Yoshikawa; Wataru Matsumiya; Kengo Akashi; Akio Morinobu; Makoto Nakamura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-01-07       Impact factor: 3.117

2.  New findings useful for clinical practice using swept-source optical coherence tomography angiography in the follow-up of active ocular toxoplasmosis.

Authors:  João Rafael de Oliveira Dias; Camila Campelo; Eduardo Amorim Novais; Gabriel Costa de Andrade; Paula Marinho; Yusláy Fernández Zamora; Luciana Finamor Peixoto; Maurício Maia; Heloísa Nascimento; Rubens Belfort
Journal:  Int J Retina Vitreous       Date:  2020-07-08

Review 3.  Advances and potential new developments in imaging techniques for posterior uveitis. Part 1: noninvasive imaging methods.

Authors:  Ilknur Tugal-Tutkun; Carl P Herbort; Alessandro Mantovani; Piergiorgio Neri; Moncef Khairallah
Journal:  Eye (Lond)       Date:  2020-07-16       Impact factor: 3.775

4.  A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer.

Authors:  Kyung Woo Kim; Sentaro Kusuhara; Motoko Tachihara; Chihiro Mimura; Wataru Matsumiya; Makoto Nakamura
Journal:  Am J Ophthalmol Case Rep       Date:  2021-03-12

5.  Assessment of patient specific information in the wild on fundus photography and optical coherence tomography.

Authors:  Marion R Munk; Thomas Kurmann; Pablo Márquez-Neila; Martin S Zinkernagel; Sebastian Wolf; Raphael Sznitman
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

Review 6.  Multimodal imaging in pediatric uveitis.

Authors:  Fitz Gerald I Diala; Kayne McCarthy; Judy L Chen; Edmund Tsui
Journal:  Ther Adv Ophthalmol       Date:  2021-12-06

7.  Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.

Authors:  Rae-Young Kim; Jae Hyun Park; Mirinae Kim; Young-Geun Park; Seok-Goo Cho; Young-Hoon Park
Journal:  PLoS One       Date:  2021-11-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.